Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors

3 Aug 2021

Abstract excerpt

A major limiting factor for systemically delivered gene therapies is the lack of novel tissue specific AAV (Adeno-associated virus) derived vectors. Bispecific antibodies can be used to redirect AAVs to specific target receptors. Here, we demonstrate that the insertion of a short linear epitope "2E3" derived from human proprotein-convertase subtilisin/kexin type 9 (PCSK9) into different surface loops of the VP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac Structural Anomalies and Repair
Share to Peptidase Inhibition and Analysis
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34361120
DOI: 10.3390/ijms22158355

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV VectorsPMID 34361120Read ↗

FAP-retargeted Ad5 enables <i>in vivo</i> gene delivery to stromal cells in the tumor microenvironmentSemantic proximity Read ↗

Unlocking precision gene therapy: harnessing AAV tropism with nanobody swapping at capsid hotspotsSemantic proximity Read ↗

Antibody-Mediated Targeting of an Adenovirus Vector Modified To Contain a Synthetic Immunoglobulin G-Binding Domain in the CapsidSemantic proximity Read ↗

Engineered AAV9 as <i>in vivo</i> gene delivery platform for the selective transduction of TME cell subsetsSemantic proximity Read ↗

Off-target-free gene delivery by affinity-purified receptor-targeted viral vectorsSemantic proximity Read ↗

Retargeting of Adenovirus Vectors through Genetic Fusion of a Single-Chain or Single-Domain Antibody to Capsid Protein IXSemantic proximity Read ↗

Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomasSemantic proximity Read ↗

A facile chemical strategy to synthesize precise AAV-protein conjugates for targeted gene deliverySemantic proximity Read ↗

Generation of human high‐affinity antibodies specific for the fibroblast activation protein by guided selectionSemantic proximity Read ↗

In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated VirusesSemantic proximity Read ↗

In vivo optical imaging of integrin αV-β3 in mice using multivalent or monovalent cRGD targeting vectorsSemantic proximity Read ↗

Unlocking Precision Gene Therapy: Harnessing AAV Tropism with Nanobody Swapping at Capsid HotspotsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.